Nectar Lifesciences Wins Income Tax Litigation for AY 2017-18; Case Concluded
Nectar Lifesciences Limited won a key income tax litigation for assessment year 2017-18. The DCIT, Chandigarh, issued an order on March 31, 2026, concluding the matter in the company's favor. This follows earlier favorable High Court rulings. The company apologized for a delay in disclosure.
The litigation has been concluded with a favorable outcome, and the financial implication is noted as 'NIL'. Therefore, the impact is considered low.
The company has received a favorable order in a tax litigation case, which is a positive development.
Nectar Lifesciences Limited has provided an update on its litigation status concerning assessment year 2017-18. The Deputy Commissioner of Income Tax (DCIT), Chandigarh, vide its order dated March 31, 2026, has disposed of the notice for this assessment year in favor of the Company.
This concludes the matter, following earlier favorable orders from the Punjab and Haryana High Court. The Company had filed writ petitions challenging notices under Sections 148 and 148A(b) of the Income Tax Act, 1961, for assessment years 2017-18 to 2021-22. The High Court had directed the Income Tax Department to dispose of the Company's objections. While objections for assessment years 2018-19 to 2021-22 were initially rejected, leading to fresh writ petitions that were allowed, the specific order for assessment year 2017-18 was received by the Company via email on April 09, 2026.
The Company expressed regret for the delay in providing these details, attributing it to the temporary inaccessibility of a former employee's registered email ID. Nectar Lifesciences assured the exchanges of its commitment to furnishing all material information within prescribed time limits in the future.
What to do with a filing like this
Nectar Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nectar Lifesciences Limited. Read the original for the full detail.